Topic: manufacturing agreement
Novo Nordisk, which has a stem cell development program for Type 1 diabetes and other diseases, now has a U.S. manufacturing facility where it can produce them.
Here's other vaccine news of note for this week.
Thermo Fisher Scientific is acquiring Patheon—the center of the consolidation that has swept through contract manufacturing—in a deal valued at $7.2 billion.
Japan’s Chugai Pharmaceutical is promising that supply of an orphan drug used to treat acute promyelocytic leukemia will not be interrupted in Japan as it transfers manufacturing and distribution of it to another company.
Since it bought out Ranbaxy Laboratories last year, Sun Pharma has been in the process of trimming back its manufacturing network of nearly 50 plants to a more manageable and efficient number. It now has a deal to unload two more facilities in the U.S.